TopoTarget gains marketing approval for its first drug  

2006.08.04
TopoTarget has received marketing approval in Europe for Savene, a damage-limiting agent for use following accidental leakage into surrounding tissue of injected anthracycline anti-cancer drugs

Danish biopharmaceutical company TopoTarget has received marketing approval in Europe for its first product Savene, a damage-limiting agent for use following accidental leakage into surrounding tissue of injected anthracycline anti-cancer drugs. Furthermore, FDA has reviewed TopoTarget's New Drug Application for Totect [the brand name used for Savene in the US – Ed], and has approved it.

Peter Buhl Jensen, CEO of TopoTarget, says: "We are proud to have provided a solution to a much-feared clinical accident. At TopoTarget our objective is to eliminate the terrible effects of accidents involving anthracyclines." TopoTarget has built up its own specialist sales force in Europe, and Savene is expected to be launched by the end of 2006.

TopoTarget is headquartered in Denmark, and has subsidiaries in Oxford UK, and in Frankfurt and Karlsruhe, Germany. The firm has a broad portfolio of small molecule preclinical drug candidates, and has eight drugs in clinical development including novel anti-cancer therapeutics. The news was reported by financial daily newspaper Børsen and on TopoTarget's website.

Link > TopoTarget 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×